We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current RCUS market cap is 1.43B. The company's latest EPS is USD -3.3786 and P/E is -4.64.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 33.58M | 33.66M | 25M | 29M | 32M |
Operating Income | -69.4M | -74.44M | -86M | -83M | -80M |
Net Income | -64.92M | -67.46M | -80M | -75M | -71M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 15M | 77.52M | 382.88M | 112M | 117M |
Operating Income | -89.91M | -124.85M | 54.25M | -280M | -340M |
Net Income | -84.71M | -122.86M | 52.83M | -267M | -307M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.39B | 1.35B | 1.25B | 1.22B | 1.19B |
Total Liabilities | 695.12M | 688M | 654M | 654M | 671M |
Total Equity | 698.7M | 657M | 600M | 566M | 520M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 203.11M | 772.29M | 1.59B | 1.35B | 1.1B |
Total Liabilities | 39.27M | 269.99M | 750.45M | 688M | 633M |
Total Equity | 163.84M | 502.3M | 841.45M | 657M | 462M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 507.74M | 438M | -98M | -155M | -218M |
Investing | -459.81M | -413M | 129M | 155M | 166M |
Financing | 21.81M | 33M | 1M | 24M | 30M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -73.46M | 111.17M | -256.17M | 438M | -306M |
Investing | 59.21M | -434.37M | -3.87M | -413M | 194M |
Financing | 1.12M | 438.68M | 237.34M | 33M | 33M |
Market Cap | 1.43B |
Price to Earnings Ratio | -4.64 |
Price to Sales Ratio | 12.19 |
Price to Cash Ratio | 11.23 |
Price to Book Ratio | 3.09 |
Dividend Yield | - |
Shares Outstanding | 90.86M |
Average Volume (1 week) | 550.15k |
Average Volume (1 Month) | 522.81k |
52 Week Change | -11.20% |
52 Week High | 25.47 |
52 Week Low | 12.95 |
Spread (Intraday) | 1.76 (10.26%) |
Company Name | Arcus Biosciences Inc |
Address |
2140 s dupont hwy camden, delaware 19934 |
Website | https://www.arcusbio.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions